

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.*

Introduced 30/09/01   Amended 01/01/11

<b>Name of entity</b>	Singular Health Group Limited
<b>ABN</b>	58 639 242 765

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Thomas Hanly
<b>Date of last notice</b>	29 December 2022

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	(1) Direct (2) Indirect
<b>Nature of indirect interest (including registered holder)</b>	Securities held by Sylvan Capital Pte Ltd - an entity controlled by Mr Hanly and of which he is a beneficiary
<b>Date of change</b>	16 March 2023
<b>No. of securities held prior to change</b>	(1)(i) 122,947 FULLY PAID ORDINARY SHARES (1)(ii) 1,500,000 CLASS A PERFORMANCE RIGHTS (1)(iii) 1,500,000 CLASS B PERFORMANCE RIGHTS (1)(iv) 6,000,000 UNLISTED OPTIONS (\$0.30, 10 FEBRUARY 2023) (1)(v) 1,500,000 PERFORMANCE RIGHTS, SUBJECT TO VESTING, EXPIRING 23 DECEMBER 2025 (2)(i) 100,000 FULLY PAID ORDINARY SHARES (2)(ii) 3,400,000 FULLY PAID ORDINARY SHARES
<b>Class</b>	(1)(i) FULLY PAID ORDINARY SHARES
<b>Number acquired</b>	56,741
<b>Number disposed</b>	NIL
<b>Value/Consideration</b>	\$4,957.25

<sup>+</sup> See [chapter 19](#) for defined terms.

<b>No. of securities held after change</b>	(1)(i) 179,688 FULLY PAID ORDINARY SHARES (1)(ii) 1,500,000 CLASS A PERFORMANCE RIGHTS (1)(iii) 1,500,000 CLASS B PERFORMANCE RIGHTS (1)(iv) 6,000,000 UNLISTED OPTIONS (\$0.30, 10 FEBRUARY 2023) (1)(v) 1,500,000 PERFORMANCE RIGHTS, SUBJECT TO VESTING, EXPIRING 23 DECEMBER 2025 (2)(i) 100,000 FULLY PAID ORDINARY SHARES (2)(ii) 3,400,000 FULLY PAID ORDINARY SHARES
<b>Nature of change</b>	On-market trade

## Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b>	N/A
<b>Interest after change</b>	N/A

## Part 3 - <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See [chapter 19](#) for defined terms.